--- title: "DBV Technologies SA (DBV) news: offering" url: "https://aibio.space/companies/dbv-technologies/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "DBV offering news: DBV Technologies sets up at-the-market program for up to $150 million of ADSs on Nasdaq. DBV Technologies SA (EURONEXT: DBV), France." --- DBV DBV Technologies SA EURONEXT · France # DBV Technologies SA (DBV) news DBV offering news Financings · 2025-09-05 ## [DBV Technologies sets up at-the-market program for up to $150 million of ADSs on Nasdaq](https://aibio.space/news/dbv-technologies-sets-up-market-program-up-150-million-adss-nasdaq/) DBV Technologies set up a $150 million at-the-market program for American Depositary Shares, sold through Citizens JMP Securities, LLC for a 3.0% commission. The prospectus supplement shows $3.86 per ADS of immediate dilution at a $9.18 reference price. ## Latest DBV Technologies SA news 1. 2025-03-31 Distress [DBV Technologies delays annual report while it works on private placement](https://aibio.space/news/dbv-technologies-delays-annual-report-while-works-private-placement/) DBV said talks on financing for its Viaskin Peanut program diverted management time. It plans to file the 10-K within the 15-day extension period. ## DBV Technologies SA at a glance - **Ticker**: DBV - **Listing**: EURONEXT - **Country**: France - **Cash, Sep 30, 2026**: $165.7 million ### Related companies - [Gensight Biologics SA](https://aibio.space/companies/gensight-biologics/) EURONEXT: SIGHT - [Poxel SA](https://aibio.space/companies/poxel/) EURONEXT: POXEL - [Ipsen SA](https://aibio.space/companies/ipsen/) EURONEXT: IPN - [Adocia SA](https://aibio.space/companies/adocia/) EURONEXT: ADOC - [Oncodesign Precision Medicine](https://aibio.space/companies/oncodesign-precision-medicine-s-a/) EURONEXT: ALOPM - [Nicox SA](https://aibio.space/companies/nicox/) EURONEXT: ALCOX - [ABIONYX Pharma SA](https://aibio.space/companies/abionyx-pharma/) EURONEXT: ABNX - [MedinCell SA](https://aibio.space/companies/medincell/) EURONEXT: MEDCL ### Also on EURONEXT - [TME Pharma](https://aibio.space/companies/tme-pharma-n-v/) ALTME - [AB Science SA](https://aibio.space/companies/science/) AB - [Nicox SA](https://aibio.space/companies/nicox/) ALCOX - [Inventiva SA](https://aibio.space/companies/inventiva/) IVA - [Innate Pharma SA](https://aibio.space/companies/innate-pharma/) IPH - [Abivax SA](https://aibio.space/companies/abivax/) ABVX ## DBV Technologies SA annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$5.6 million](https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/) | [$4.2 million](https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/) | | Research and development | [$116.7 million](https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/) | [$89.3 million](https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/) | | Net income (loss) | [-$146.9 million](https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/) | [-$113.9 million](https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/) | | Cash from operations | [-$121.2 million](https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/) | [-$104.5 million](https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/) | | Cash and equivalents | [$194.2 million](https://www.sec.gov/Archives/edgar/data/1613780/000162828026067930/) | [$32.5 million](https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $165.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about DBV Technologies SA Has DBV Technologies SA raised money recently? Our latest story on this, dated Sep 5, 2025: "DBV Technologies sets up at-the-market program for up to $150 million of ADSs on Nasdaq". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/dbv-technologies-sets-up-market-program-up-150-million-adss-nasdaq/). What is the ticker symbol of DBV Technologies SA? DBV Technologies SA trades under the ticker DBV on EURONEXT. Where is DBV Technologies SA listed? DBV Technologies SA is listed on EURONEXT. Our directory also records these other listings: DUS:DBV; FWB:DBV; GETTEX:DBV; HAM:DBV; HAN:DBV; LS:A1JWB7; LSIN:0QAJ; LSX:A1JWB7; MUN:DBV; NASDAQ:DBVT; SWB:DBV; TRADEGATE:DBV; XETR:DBV. What is the SEC CIK of DBV Technologies SA? The SEC Central Index Key (CIK) for DBV Technologies SA is 1613780. Its filings are on SEC EDGAR. How many shares does DBV Technologies SA have outstanding? 296,061,497 shares as of 2026-07-16, per the cover page of its 10-Q filed 2026-07-16. Which country or territory is DBV Technologies SA listed under? Our directory records DBV Technologies SA under France. What does DBV Technologies SA do? Our directory classifies DBV Technologies SA as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of DBV Technologies SA? The ISIN recorded for DBV Technologies SA is FR0010417345. Does aibio.space cover DBV Technologies SA? aibio.space lists DBV Technologies SA among 2,820 public biotech companies and publishes its news here as stories appear. Where is DBV Technologies SA incorporated? SEC records list its state or country of incorporation as I0. What was DBV Technologies SA's revenue last year? $5.6 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is DBV Technologies SA profitable? DBV Technologies SA reported a net loss of $146.9 million for the fiscal year ended Dec 31, 2025, and used $121.2 million of cash in operations, per its annual report to the SEC. How much does DBV Technologies SA spend on research and development? $116.7 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does DBV Technologies SA have? $165.7 million in cash at Sep 30, 2026, per its 10-Q. What is the latest DBV Technologies SA (DBV) stock news? Our latest story on DBV Technologies SA, dated Sep 5, 2025: "DBV Technologies sets up at-the-market program for up to $150 million of ADSs on Nasdaq". DBV Technologies set up a $150 million at-the-market program for American Depositary Shares, sold through Citizens JMP Securities, LLC for a 3.0% commission. The prospectus supplement shows $3.86 per ADS of immediate dilution at a $9.18 reference price. [Source](https://aibio.space/news/dbv-technologies-sets-up-market-program-up-150-million-adss-nasdaq/). ## Investor discussion: DBV Technologies SA Members talk about DBV Technologies SA (DBV). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at DBV Technologies SA, newest first. Each line links the filing it comes from. 1. 2026-07-27 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. [Source](https://www.sec.gov/Archives/edgar/data/1613780/000119312526316910/d119199ds3asr.htm) 2. 2026-01-20 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1613780/000119312526015592/d74681dex991.htm) 3. 2025-12-16 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1613780/000119312525320901/d28682dex991.htm) 4. 2025-09-05 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1613780/000119312525197205/d785485d424b5.htm) 5. 2025-07-29 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1613780/000161378025000016/dbvt-20250630.htm) 6. 2025-05-15 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1613780/000119312525120788/d929667ddef14a.htm) 7. 2025-05-05 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1613780/000119312525112793/d929667dpre14a.htm) 8. 2025-03-31 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1613780/000119312525068727/d944342dex991.htm) 9. 2025-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1613780/000119312525068795/d848890dnt10k.htm) 10. 2024-12-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1613780/000119312524279571/d891585d8k.htm) 11. 2024-11-12 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1613780/000119312524255153/d866073dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open EURONEXT:DBV on TradingView](https://www.tradingview.com/symbols/EURONEXT-DBV/). ## SEC filings and registration - **SEC name**: DBV Technologies S.A. - **CIK**: 1613780 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: DBVT (Nasdaq), DBVTF (OTC) - **State or country of incorporation**: I0 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 107 AVENUE DE LA REPUBLIQUE, CHATILLON - **Phone**: 330155427878 - **Shares outstanding**: 296,061,497 as of 2026-07-16 (10-Q filed 2026-07-16) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1613780/000119312526408052/d118963d8k.htm) filed 2026-09-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1613780/000119312526306222/d156695d8k.htm) filed 2026-07-16 - [10-Q](https://www.sec.gov/Archives/edgar/data/1613780/000162828026048453/dbvt-20260630.htm) filed 2026-07-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1613780/000119312526288533/d108693d8k.htm) filed 2026-06-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1613780/000119312526259488/d139789d8k.htm) filed 2026-06-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1613780/000119312526255414/d107628d8k.htm) filed 2026-06-03 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1613780/000119312526215657/d59776ddef14a.htm) filed 2026-05-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1613780/000119312526206315/d150727d8k.htm) filed 2026-05-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001613780), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details DBV Technologies SA is a public biotech or pharmaceutical company listed on EURONEXT under the ticker DBV, recorded under France. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: DBV Technologies SA - **Ticker**: DBV - **Listing**: EURONEXT - **Country or territory**: France - **Business scope**: Pharmaceuticals: Major - **ISIN**: FR0010417345 - **Other listed symbols**: DUS:DBV; FWB:DBV; GETTEX:DBV; HAM:DBV; HAN:DBV; LS:A1JWB7; LSIN:0QAJ; LSX:A1JWB7; MUN:DBV; NASDAQ:DBVT; SWB:DBV; TRADEGATE:DBV; XETR:DBV - **Last quote in directory**: 2026-10-22 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/EURONEXT-DBV/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/dbv-technologies/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "DBV Technologies SA (DBV) news: offering", 2026-10-31, https://aibio.space/companies/dbv-technologies/